Crispr Therapeutics Ownership
| CRSP Stock | USD 38.77 3.17 8.90% |
Shares in Circulation | First Issued 2015-03-31 | Previous Quarter 85.5 M | Current Value 85.9 M | Avarage Shares Outstanding 59 M | Quarterly Volatility 22.1 M |
Crispr Stock Ownership Analysis
About 74.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.72. Some equities with similar Price to Book (P/B) outperform the market in the long run. Crispr Therapeutics recorded a loss per share of 4.49. The entity had not issued any dividends in recent years. The firm had 333333:100 split on the 19th of July 2016. CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 platform. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. CRISPR Therapeutics is traded on NASDAQ Exchange in the United States. For more info on Crispr Therapeutics AG please contact the company at 41 41 561 32 77 or go to https://www.crisprtx.com.Besides selling stocks to institutional investors, Crispr Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Crispr Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Crispr Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Crispr Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Crispr Therapeutics Insider Trades History
Only 1.75% of Crispr Therapeutics AG are currently held by insiders. Unlike Crispr Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Crispr Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Crispr Therapeutics' insider trades
Crispr Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Crispr Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Crispr Therapeutics AG backward and forwards among themselves. Crispr Therapeutics' institutional investor refers to the entity that pools money to purchase Crispr Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Orbis Allan Gray Ltd | 2024-12-31 | 1.5 M | Ecor1 Capital, Llc | 2024-12-31 | 1.4 M | Baker Bros Advisors Lp | 2024-12-31 | 1.3 M | Bank Of America Corp | 2024-12-31 | 1.2 M | Sr One Capital Management, Lp | 2024-12-31 | 1 M | Geode Capital Management, Llc | 2024-12-31 | 1 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 947.3 K | Loomis, Sayles & Company Lp | 2024-12-31 | 911 K | Balyasny Asset Management Llc | 2024-12-31 | 893.9 K | Ark Investment Management Llc | 2024-12-31 | 9 M | Capital Research & Mgmt Co - Division 3 | 2024-12-31 | 8.7 M |
Crispr Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Crispr Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Crispr Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Crispr Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bruno Julianne over two months ago Disposition of 190 shares by Bruno Julianne of Crispr Therapeutics at 43.32 subject to Rule 16b-3 | ||
Samarth Kulkarni over three months ago Disposition of 23121 shares by Samarth Kulkarni of Crispr Therapeutics at 55.43 subject to Rule 16b-3 | ||
Samarth Kulkarni over three months ago Disposition of 13751 shares by Samarth Kulkarni of Crispr Therapeutics at 16.21 subject to Rule 16b-3 | ||
Samarth Kulkarni over six months ago Disposition of 20000 shares by Samarth Kulkarni of Crispr Therapeutics at 19.12 subject to Rule 16b-3 |
Crispr Therapeutics' latest congressional trading
Congressional trading in companies like Crispr Therapeutics, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Crispr Therapeutics by those in governmental positions are based on the same information available to the general public.
| 2021-01-15 | Senator James Inhofe | Acquired Under $15K | Verify |
Crispr Therapeutics Outstanding Bonds
Crispr Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Crispr Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Crispr bonds can be classified according to their maturity, which is the date when Crispr Therapeutics AG has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Crispr Therapeutics Corporate Filings
| 14th of May 2025 Other Reports | ViewVerify | |
8K | 6th of May 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 16th of April 2025 Other Reports | ViewVerify | |
| 3rd of April 2025 Other Reports | ViewVerify |
Pair Trading with Crispr Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Crispr Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Crispr Stock
Moving against Crispr Stock
| 0.65 | ANIP | ANI Pharmaceuticals | PairCorr |
| 0.52 | CWT | California Water Service | PairCorr |
| 0.38 | RGC | Regencell Bioscience | PairCorr |
| 0.37 | WHLRD | Wheeler Real Estate | PairCorr |
The ability to find closely correlated positions to Crispr Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Crispr Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Crispr Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Crispr Therapeutics AG to buy it.
The correlation of Crispr Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Crispr Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Crispr Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Crispr Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Crispr Stock Analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.